Improving Cognitive Function in Aging- Related Dementia

SLU ID 17-040 | Peptide for Treating Aging-Related Dementia

Intellectual Property Status

Seeking

  • Provisional patent application submitted
  • Know-how based
  • Licensee
  • Development partner
  • Commercial partner

Background

Dementia is a broad category of brain diseases that cause a gradual, long-term decrease in cognitive function that negatively affects a person’s daily functions. While dementia usually does not affect an individual’s awareness, it often produces other symptoms including emotional problems, language difficulties, and decreased motivation. Currently there are no therapies approved for treating aging-related dementia.

Overview

Researchers at Saint Louis University have advanced the knowledge about the neural signaling pathways involved in dementias and demonstrated that the administration of adropin (AdrTG) in the brain and periphery may delay or prevent declines in learning and memory with aging.

Benefits

The potential advantages of this technology over existing solutions include:

  • Increase the number of therapies for treating dementia.
  • Minimize the risk of developing dementia.
  • Minimize the cognitive impairment associated with dementia.
  • Minimize the negative impact on quality of life for individuals suffering from dementia

Applications

This technology has potential application in treating aging-related dementia.

Opportunity

Saint Louis University is seeking partners to further develop and commercialize this technology.